Mar. 23 -- WEDNESDAY, Aug. 15 (HealthDay News) -- For the first time, scientists say they have identified an immune molecule that may predict prostate cancer recurrence after surgery. "We discovered a ...
A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that stereotactic body radiotherapy (SBRT), a form of high-dose radiation delivered in just five sessions, after ...
Findings from the UCLA-led trial showed that men who received the radioligand drug went a median of 17.6 months without disease progression, compared with 7.4 months for those who received SBRT alone.
A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery — the ...